BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27275535)

  • 1. Loss of insulin-like growth factor II imprinting is a hallmark associated with enhanced chemo/radiotherapy resistance in cancer stem cells.
    Zhao X; Liu X; Wang G; Wen X; Zhang X; Hoffman AR; Li W; Hu JF; Cui J
    Oncotarget; 2016 Aug; 7(32):51349-51364. PubMed ID: 27275535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
    Wang H; Ge S; Qian G; Li W; Cui J; Wang G; Hoffman AR; Hu JF
    Exp Cell Res; 2015 Nov; 338(2):214-21. PubMed ID: 26407907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines.
    Li T; Chen H; Li W; Cui J; Wang G; Hu X; Hoffman AR; Hu J
    Hum Mol Genet; 2014 Jan; 23(1):117-28. PubMed ID: 23962719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells.
    Vu TH; Nguyen AH; Hoffman AR
    Hum Mol Genet; 2010 Mar; 19(5):901-19. PubMed ID: 20015958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for cancer through adenovirus vector‑mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting.
    Pan Y; He B; Lirong Z; Nie Z; Chen L; Gu L; Hoffman AR; Wang S; Hu J
    Oncol Rep; 2013 Oct; 30(4):1814-22. PubMed ID: 23900345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of down-regulation of IGF2 gene on the biological characteristics of HCT116 colon cancer stem cells].
    Zhao X; Li J; Liu HQ; Liu XL
    Zhonghua Zhong Liu Za Zhi; 2019 Aug; 41(8):580-586. PubMed ID: 31434448
    [No Abstract]   [Full Text] [Related]  

  • 7. CRISPR Cas9-guided chromatin immunoprecipitation identifies miR483 as an epigenetic modulator of IGF2 imprinting in tumors.
    Zhang Y; Hu JF; Wang H; Cui J; Gao S; Hoffman AR; Li W
    Oncotarget; 2017 May; 8(21):34177-34190. PubMed ID: 27486969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF2 loss of imprinting enhances colorectal cancer stem cells pluripotency by promoting tumor autophagy.
    Gao T; Liu X; He B; Pan Y; Wang S
    Aging (Albany NY); 2020 Nov; 12(21):21236-21252. PubMed ID: 33173015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.
    Küffer S; Gutting T; Belharazem D; Sauer C; Michel MS; Marx A; Trojan L; Ströbel P
    Mol Oncol; 2018 Feb; 12(2):256-266. PubMed ID: 29239100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells.
    Hofmann WK; Takeuchi S; Frantzen MA; Hoelzer D; Koeffler HP
    Exp Hematol; 2002 Apr; 30(4):318-23. PubMed ID: 11937266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system.
    Pan Y; He B; Chen J; Sun H; Deng Q; Wang F; Ying H; Liu X; Lin K; Peng H; Xie H; Wang S
    Int J Oncol; 2015 Nov; 47(5):1881-9. PubMed ID: 26397886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.
    Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP
    J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the promoter-specific imprinting of the insulin-like growth factor-II gene in Wilms' tumor.
    Vu TH; Hoffman A
    J Biol Chem; 1996 Apr; 271(15):9014-23. PubMed ID: 8621549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive methylation analysis of imprinting-associated differentially methylated regions in colorectal cancer.
    Hidaka H; Higashimoto K; Aoki S; Mishima H; Hayashida C; Maeda T; Koga Y; Yatsuki H; Joh K; Noshiro H; Iwakiri R; Kawaguchi A; Yoshiura KI; Fujimoto K; Soejima H
    Clin Epigenetics; 2018 Dec; 10(1):150. PubMed ID: 30509319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma.
    Lawson EA; Zhang X; Crocker JT; Wang WL; Klibanski A
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2226-31. PubMed ID: 19383775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
    Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
    Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.
    Bhusari S; Yang B; Kueck J; Huang W; Jarrard DF
    Prostate; 2011 Nov; 71(15):1621-30. PubMed ID: 21432864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
    Murphy SK; Huang Z; Wen Y; Spillman MA; Whitaker RS; Simel LR; Nichols TD; Marks JR; Berchuck A
    Mol Cancer Res; 2006 Apr; 4(4):283-92. PubMed ID: 16603642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
    Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
    Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.
    Fu VX; Dobosy JR; Desotelle JA; Almassi N; Ewald JA; Srinivasan R; Berres M; Svaren J; Weindruch R; Jarrard DF
    Cancer Res; 2008 Aug; 68(16):6797-802. PubMed ID: 18701505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.